Patents
Literature
3 results about "Reactogenicity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In clinical trials, the term reactogenicity refers to the property of a vaccine of being able to produce common, "expected" adverse reactions, especially excessive immunological responses and associated signs and symptoms—fever, sore arm at injection site, etc. (Much less frequently, the term has also been applied to therapeutic drug trials.) Other manifestations of reactogenicity typically assessed in such trials include bruising, redness, induration, and swelling.
A broad-spectrum protective antigen of avibacterium paragallinarum and use thereof
ActiveCN120136983BBacterial antigen ingredientsAntibacterial agentsProtective antigenInfectious Disorder
The application discloses a broad-spectrum protective antigen of avian pathogenic bacterium and application thereof, and belongs to the field of poultry infectious disease prevention and control. The application provides application of avian pathogenic bacterium protein p1 in preparation of a broad-spectrum protective antigen protein of avian pathogenic bacterium, and the amino acid sequence of the avian pathogenic bacterium protein p1 is shown as SEQ ID No. 1. The protective antigen protein has strong immunogenicity and reactivity, and a subunit vaccine prepared by using the antigen protein can provide 90% protection rate of chickens to A, B and C three serotypes of avian pathogenic bacterium, and can effectively prevent infection of the avian pathogenic bacterium.
Owner:YANGZHOU UNIV
A coated protein, applications and kits for diagnosis of antibodies to african swine fever virus
ActiveCN121270667BVirus peptidesMaterial analysisAfrican swine fever virus AntibodyProteinogenic amino acid
The application belongs to the field of biology, and discloses a coated protein, application and kit for diagnosing African swine fever virus antibody, wherein the coated protein comprises p22 protein and E199L protein; the amino acid sequence of the p22 protein is shown as SEQ ID NO:1, and the amino acid sequence of the E199L protein is shown as SEQ ID NO:3. The coated protein is composed of recombinant proteins of p22 and E199L, and both of the two kinds of recombinant proteins can react with ASF positive serum, and both have good reactivity. The detection kit based on the above coated protein has high detection precision, strong specificity and good repeatability.
Owner:GUANGZHOU YUEYANG BIOLOGICAL TECH CO LTD
Multi-link b cell epitope recombinant protein for detecting anti-brucella antibody and application thereof
The application discloses a kind of detection anti-Brucella antibody multi-link B cell epitope recombinant protein and its application, it belongs to the field of biotechnology and immunodiagnosis technique, wherein, multi-link B cell epitope recombinant protein is formed by the B cell epitope of seven key outer membrane proteins Omp10, Omp16, Omp19, Omp25, Omp31, Omp2b, BP26 of Brucella, its amino acid sequence is as shown in sequence table SEQ ID NO:1.The multi-link B cell epitope recombinant protein has good antigenicity and reactivity, and the deer serum indirect ELISA detection system established with it as coating antigen shows excellent detection performance, has high sensitivity, strong specificity and good repeatability, and can accurately detect the level of anti-Brucella antibody in deer serum sample.
Owner:JILIN UNIVERSITY